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Immune System as a Target Organ
for Toxicity
by Peter H. Bick*
Recently, interest has centered on the immune system as a target organ for toxic effects. This
seems a reasonable choice, since it can be argued that alterations induced in this system as a
result of a toxic insult could lead to impaired immunity. Such an alteration may be manifest in
altered disease susceptibility. Documenting toxic effects upon the immune system is a difficult
task due to the multifaceted network of specialized cells that carry out immune functions.
Because of this complexity, it is necessary to develop a panel of immunologic assays to
adequately cover the diverse functions that may be affected by a toxic substance. In the interest
of efficiency and cost, it is preferable to organize the assay systems into a tier structure to
generate the most information in the shortest time. An overview of the immune system is
presented, and an example of one possible tier system of assays is described.
Introduction
As a target organ for toxicity the immune
system is, at first glance, a logical choice to
investigate. One could reason that prolonged expo-
sure to a substance of low toxicity or an acute
exposure to a highly toxic chemical may alter
immunological functions and predispose an indi-
vidual to increased disease susceptibility. In prac-
tice, however, documenting such effects is not the
easy task one would hope for. This is due to the
nature of the immune system, which comprises a
large network of organs and varied cell types that
carry out interrelated functions. Many of the
cellular subpopulations are highly specialized, and
there exist numerous avenues of communication
and a complex regulatory network that governs
responsiveness (1). Of selective advantage to the
host is the fact that the immune system offers
several pathways for handling a challenge. This
fact alone complicates toxicologic studies by allowing
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the possibility of a protective immune response to
coincide with a toxic effect. A component of one
pathway may be compromised by a toxic insult,
yet the host's ability to survive a challenge by an
infectious agent may be unchanged. Immunotox-
icological studies therefore must be multifaceted to
detect such situations.
It is desirable to establish a set of immunologic
tests that could be applied to the study of the
toxicological properties of a wide range of sus-
pected substances. Such a battery of tests should
have the following characteristics: (a) a standard-
ized test panel should be based on sound cellular
immunologic techniques; (b) the test panel should
be as sensitive and reproducible as possible to
facilitate data comparison between laboratories;
and (c) the test systems should be as automated as
possible to allow sufficient data to be generated
from a statistically large sample population. The
limitations of each test in relation to what is
learned concerning the function of the immune
system as a whole should be considered. In order
to reach this goal, one must have an overall
appreciation of the complexity of the immune
system.
3Development, Structure
and Function of the
Immune System
Cells of the immune system originate from a
pluripotent stem cell pool found in the yolk sac and
fetal liver during fetal development and in the
bone marrow and spleen of the adult (2-4). As
shown in Figure 1, stem cells may follow one of
several lines of maturation. Influential in the
development of one major lymphocyte class is the
thymus, which originates from the third and fourth
pharyngeal pouches at 9 days of gestation in mice,
(9 weeks in man). As stem cells pass through and
are influenced by the thymus, they mature and
acquire the characteristics of thymus-derived T-
lymphocytes on their way into the peripheral
lymphoid organs. Mature T-lymphocytes seed the
thymic-dependent areas of the spleen and lymph
nodes and comprise 55-74% ofthe peripheral blood
lymphocytes (5, 6). These cells can be distinguished
from other lymphocytes by genetically defined
alloantigenic cell surface markers: Thy 1 (theta)
and Lyt 1, 2, and 3 (in mice), among others (7-9).
Such cell surface markers provide handles with
which toidentify functional subpopulations ofT-cells
in normal and disease states. T-lymphocytes also
respond to the mitogens phytohemagglutinin (PHA)
and concanavalin A (con A), which can be used as a
gross probe for the integrity of T-cell function (10,
11). T-cells carry out functions of immune regula-
tion by participating as amplifying "helper" cells
and "suppressor" cells active in antibody responses
to thymic-dependent antigens, mixed lymphocyte
responses, delayed-type hypersensitivity (DTH)
reactions and the activation of cytotoxic effector
T-cells. Effector T-cells participate directly as
killer cells against virally infected host cells, malig-
nant cells and foreign tissue, function in DTH
reactions and elaborate soluble lymphokine media-
tors capable of modulating inflammation. T-cells
are long-lived lymphocytes, and the thymus atro-
phies in the adult animal. Some estimates of
longevity place some T-cells as existing for 15-20
years. Since there is little replacement of T-cells,
alterations in this compartment may be very
detrimental. Lesions in the T-cell system result in
enhanced susceptibility to viral, fungal and para-
sitic infections and alter the levels of most anti-
body responses. Depletion of the thymus gland or
stem cell pool during fetal development decimates
this branch of the immune response as demon-
strated by patients with DiGeorge syndrome.
Alterations in discrete T-cell subsets may alter
immune responses in a selective manner. For
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example, patients with systemic lupus erythematosis
have below normal suppressor T-cell function,
resulting in unregulated antibody production (12-16).
Evaluation of T-cell function should include test
parameters that detect functional activity of the
various T-cell subpopulations.
The second major route oflymphocytes differen-
tiation is well defined in avian species. Here the
Bursa of Fabricius processes stem cells to become
mature B-lymphocytes. No such organ can be
defined in mammals, and several sites for B-
lymphocyte maturation have been suggested, includ-
ing bone marrow, spleen and the gut-associated
lymphoid tissue. Lymphocytes that follow this
pathway become mature B-lymphocytes that pos-
sess specific immunoglobulin receptors on the cell
surface that are of the same specificity as the
antibody to be produced by the cell following
activation. The high density of cell surface immu-
noglobulin (sIg) is a central characteristic that
separates B- fromT-lymphocytes. As B-lymphocytes
mature from stem cells, a number of cell surface
changes occur. B-lymphocytes progress from a
"pre-B" cell with no surface immunoglobulin to an
immature sIgM-bearing cell. Subsequent differ-
entiative steps see the B-cell sequentially acquir-
ing receptors for the Fc portion of IgG, cell
surface IgD, immune-response associated (Ia) anti-
gens coded for by the major histocompatibility
complex and receptors for complement compo-
nents (17-21). B-lymphocytes with differing cell
surface phenotypes represent functionally differ-
ent subpopulations that respond differentially to
tolerance induction and antigenic and mitogenic
stimulation (22-24). The cell surface markers can
be used to delineate and identify alterations in
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FIGURE 1. Development and organization of the cellular
immune system
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ified B-cell populations. Antisera specific for many
of the cell surface markers (sIg, Ia) are commer-
cially available, some as hybridoma antibodies,
allowing widespread application of phenotype deter-
mination and cell depletion. Mature B-lymphocytes
are found in the thymic-independent areas of
spleen and lymph nodes and represent approxi-
mately 25-45% of peripheral blood lymphocytes.
Following activation, B-lymphocytes proliferate
and/or differentiate into antibody-producing cells
and plasma cells. As this process proceeds, many
cell surface markers are lost, and the end-stage
plasma cell expresses a new antigen (plasma cell
antigen, Pca) and produces quantities of specific
immunoglobulin. In contrast to the long-lived T-cell,
B-cells turn over frequently and are replaced by
newly differentiating stem cells. Alterations in the
B-cell compartment may be reversible following
the differentiation of new adult B-cells. Toxic
insults that result in depletion of B-cell function
can result in lowered immunoglobulin levels and
increased susceptibility to bacterial infection.
Other lymphocytic cells active in immune cytotoxic
functions are the natural killer (NK) cell and the
"null" cell active in antibody-dependent cell-
mediated cytotoxicity (ADCC). Natural killer cells
have cytotoxic potential for certain malignant cells
in the absence of prior sensitization. These cells
probably represent pre-T cells but do not exhibit
traditional T-cell phenotypes (25-27). The null cells
active in ADCC do not bear traditional B-cell
markers but possess receptors for IgG Fc and
some T-cell markers and are capable of killing
antibody-coated target cells (28). The differentia-
tion pathways ofthese cells are not as well defined
as are those of the T and B lymphocytes. The
observation that cells active in ADCC bear some
T-cell markers suggests that these cells evolve
from the T-cell lineage and that the ADCC and
NK effector cell populations may overlap (29-31).
Although there exist mouse strains that are deficient
in NK activity [Beige mice; C57BL/6J-bg (32, 33)],
it is not clear what the long-range effects of
defects in ADCC or NK activity may be. These
functions may be compensated forby T-lymphocyte
functions.
The pluripotent stem cell pool also contains the
precursors of monocyte-macrophage and polymor-
phonuclear leukocyte (PMN) populations. The mac-
rophage has an important role in genetically defined
antigen-driven immune activation and tumor-cell
killing in addition to its phagocytic role. Defects in
stem cell differentiation into PMN's or macro-
phages will predispose the host to bacterial infec-
tion and in the case of a macrophage defect will
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interrupt normal B- and T-lymphocyte activation.
As should be clear from the above discussion,
toxicological alterations may affect the immune
system in a very subtle or gross fashion depending
upon the level of interference. If a single T- or
B-cell subpopulation is affected, the loss of overall
responsiveness and increase in disease susceptibil-
ity may be minimal. Such a loss of response may
also be transient. However, an alteration in stem
cell, thymus or bone marrow differentiative path-
way may result in severe nonreversible impair-
ment. It is important, therefore, to study a wide
range of parameters in order accurately to assess
any effect on the immune system as a whole.
Assessment of Immunologic
Potential
Various immune assay systems measure differ-
ent levels of cell involvement and complexity in
response to a stimulus. As such, assays that
measure responses that are a result ofcomplex cell
interaction mechanisms are more likely to reveal
alterations in immune function. For this reason,
one can order the immunologic parameters into a
tier structure, based on sequential levels of cellu-
lar cooperation reflecting this degree of complexi-
ty. It is anticipated that studies of drug- or
chemical-induced immune alterations would focus
on the complex assay systems first. Once a drug-
induced lesion is found, the cause can be dissected
using assays that involve less complex systems.
Such an approach will ultimately lead to the assays
that will pinpoint the cellular basis of dysfunction.
Table 1 shows one possible tier structure. This tier
system is not meant to be exhaustive but to serve
as an example ofone possible experimental design.
The components of Tier I measure reactions that
depend upon complex multicellular interactions
involving T and B lymphocytes and macrophages.
Genetically controlled regulatory networks play an
important role in these responses. It would be
anticipated that immune alterations at one of
several sites in the cell interaction network would
result in a modified response. However, since
these systems are complex, it may be possible to
compensate for an immune lesion by using an
alternative response pathway. Furthermore, since
these systems only assess a limited area of the
total immune system several should be employed
to provide good coverage.
The assay systems in Tier II involve cell inter-
action mechanisms that are less complex than
those in Tier I, often inducing only M4-T-cell or
B-cell-M4-suppressorT-cellinteractions. Theseassay
5Table 1. Hierarchy of some immunologic assay systems.
Tier Reaction
Tier I Complex cell interactions
In vivo spleen cell IgM and IgG responses to
thymic-dependent antigens
Popliteal lymph node proliferation following
immunization
Delayed cutaneous hypersensitivity
Quantitation ofcirculating antibody levels following
immunization with thymic-dependent and thymic-
independent antigens
Tier II Immunologic interactions ofintermediate complexity
Determination of basal immunoglobulin levels
Mitogenic stimulation ofT-lymphocytes with
cbncanavalin A or phytohemagglutinin
Stimulation of B-cell proliferation and antibody
synthesis by E. coli lipopolysaccharide
One-way mixed lymphocte reactivity
Enumeration ofthioglycollate-induced peritoneal
exudate cells
Tier III Direct cellular assays
Determination ofresident mouseperitoneal exudate
cells
Determination ofphagocytic capacity of peritoneal
exudate cells
Cytostatic and cytotoxic capability ofadherent
normal and activated resident peritoneal exudate
cells against malignant cells
Reticuloendothelial system clearance
systems allow a more defined evaluation of a
discrete portion of the immune response. As such
they may allow a chemically induced effect detected
in a Tier I assay to be localized to a particular cell
type. Further definition of a toxic effect may be
accomplished using direct cellular assays like those
presented in Tier III.
Assays shown in Tier III represent some of the
assays available to determine the function of a
distinct cell population. Once it is suspected that a
discrete cell population is affected by a chemical,
assays of this type are useful in supporting the
initial findings. By ordering the experimental pro-
tocols in a tier structure, a drug-induced alteration
in immune responsiveness is likely to be rapidly
detected and efficiently defined.
Conclusion
The immune response offers a well-defined sys-
tem in which to study the toxic effects of sus-
pected drugs or chemicals. Through many years of
immunologic research our understanding of the
complexity of the cellular interactions involved in
any immune response allows us to ask specific
toxicological questions. The following considera-
tions are important in any immunotoxicological
study. The immune system represents a complex
multicellular, multiorgan network that may be
affected at several sites. Alterations in one arm of
the response (humoral or cellular) may not affect
responses governed bythe otherlimb. The immune
system shows a great deal ofresiliency and harm-
ful effects may be transient. Some components of
theimmune systemare long-lived (T-cells), whereas
others are not (B-cells). Alterations in short-lived,
replaceable systems may have little long-term
consequence to the host. Immune response capa-
bility and the influence of various organs (thymus)
changes with ages. Therefore deleterious effects
may be a function of age. Since many immune
responses are genetically controlled, alterations in
responsiveness to one challenge in a given animal
model may not hold true in second animal model.
Genetic differences may also be seen between
sexes.
In view of the above considerations it is impor-
tant in any toxicological study of immune capacity
to consider the immune system as a whole and
design experimental protocols that consider the
dynamic complexity ofthe system.
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